Abstract PR14: E x vivo models of pancreatic cancer that recapitulate the metabolic tumor microenvironment identify glycine as a chemoresistance-inducing oncometabolite
Guillaume Cognet,Colin Sheehan,Grace Croley,Lyndon Hu,Alexander Muir
DOI: https://doi.org/10.1158/1538-7445.panca2023-pr14
IF: 11.2
2024-01-18
Cancer Research
Abstract:Pancreatic adenocarcinoma (PDAC) tumors are poorly perfused due to intense desmoplasia and dysfunctional vasculature. This limited perfusion leads to abnormal availability of nutrients and metabolic substrates in the tumor microenvironment. To understand how microenvironmetnal nutrient availability impacts PDAC biology, we performed quantitative metabolomics of the interstitial fluid (the local perfusate) of PDAC tumors to comprehensively characterize nutrient availability in the PDAC microenvironment. We have used this information to develop Tumor Interstitial Fluid Medium (TIFM), a cell culture medium that contains nutrient levels representative of the PDAC microenvironment, enabling the study of PDAC biology under physiological nutrition. By transcriptomic analysis, we show that PDAC cells cultured in TIFM, compared to standard ex vivo models, adopt a cellular state more similar to PDAC cells in tumors, identifying TME nutrient availability as a key microenvironmental factor regulating PDAC biology in vivo. Given that PDAC cells in TIFM adopt an in vivo-like cell state, we next asked if PDAC cells in TIFM would exhibit phenotypes that PDAC cells primarily exhibit in vivo, such as resistance to chemotherapeutic treatment. We found that TIFM culture dramatically increases the resistance of PDAC cells to chemotherapeutic challenge. As TIFM is chemically defined, we systemically screened microenvironmental nutrient cues to identify those triggering therapy resistance. We found that glycine, an amino acid that accumulates to high levels in the PDAC microenvironment, was necessary and sufficient to cause PDAC therapy resistance. Glycine, at the concentrations found in the PDAC microenvironment, has been found to broadly cytoprotective by inhibiting cell death elicited by diverse cellular stresses. In mechanistic experiments, we similarly find that microenvironmental glycine does not prevent chemotherapeutic damage of PDAC cells but blocks cell death in response to this damage. Thus, we propose glycine is a novel oncometabolite that PDAC tumors accumulate, enabling them to cope with diverse stresses, including chemotherapeutic challenge. Altogether, these data show that nutrient availability in the microenvironment is an important determinant of PDAC biology, and models incorporating tumor nutrition can enable mechanistic study of microenvironmentally-programmed PDAC phenotypes. Citation Format: Guillaume Cognet, Colin Sheehan, Grace Croley, Lyndon Hu, Alexander Muir. Ex vivo models of pancreatic cancer that recapitulate the metabolic tumor microenvironment identify glycine as a chemoresistance-inducing oncometabolite [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr PR14.
oncology
What problem does this paper attempt to address?